US2019153394A1PendingUtilityA1

Generation of pancreatic endoderm from pluripotent stem cells using small molecules

Assignee: NOVO NORDISK ASPriority: Sep 3, 2012Filed: Jan 23, 2019Published: May 23, 2019
Est. expirySep 3, 2032(~6.1 yrs left)· nominal 20-yr term from priority
C12N 2503/02C12N 2501/115C12N 2501/727C12N 2501/385C12N 2501/16C12N 2501/119C12N 2501/415C12N 5/0676C12N 2501/999C12N 2501/60C12N 2506/02C12N 2501/155C12N 2501/117C12N 2506/45C12N 2501/41C12N 5/0678
55
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method of producing pancreatic cells or pancreatic cell precursors expressing at least 5% PDX1/NKX6.1 double positive, comprising exposing definitive endoderm cells to an effective amount of one or more small molecules, to differentiate the human definitive endoderm cells into the pancreatic cells or pancreatic cell precursors. The present invention also relates to pancreatic endoderm cells produced by said methods and uses of said pancreatic endoderm cells.

Claims

exact text as granted — not AI-modified
1 . A cell culture medium comprising definitive endoderm cells, a BMP inhibitor, JNK inhibitor II, bFGF, and a retinoic acid receptor agonist. 
     
     
         2 . The cell culture medium of  claim 1 , wherein the BMP inhibitor is 
       
         
           
           
               
               
           
         
       
     
     
         3 . The cell culture medium of  claim 1 , wherein the retinoic acid receptor agonist is 
       
         
           
           
               
               
           
         
       
     
     
         4 . The cell culture medium of  claim 1 , wherein the BMP inhibitor is 
       
         
           
           
               
               
           
         
         and the retinoic acid receptor agonist is

Join the waitlist — get patent alerts

Track US2019153394A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.